Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Large Decline in Short Interest

Aytu BioPharma, Inc. (NASDAQ:AYTU) was the recipient of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 120,800 shares, a decline of 37.3% from the October 31st total of 192,800 shares. Based on an average trading volume of 29,500 shares, the days-to-cover ratio is currently 4.1 days. Currently, 2.0% of the company’s shares are sold short.

Aytu BioPharma Trading Up 1.3 %

Shares of Aytu BioPharma stock traded up $0.02 during trading on Thursday, reaching $1.62. The company’s stock had a trading volume of 34,083 shares, compared to its average volume of 22,946. The company has a quick ratio of 0.80, a current ratio of 0.99 and a debt-to-equity ratio of 0.35. Aytu BioPharma has a 52-week low of $1.41 and a 52-week high of $3.45. The firm’s 50-day moving average is $2.06 and its two-hundred day moving average is $2.52. The company has a market cap of $9.96 million, a price-to-earnings ratio of -1.32 and a beta of -1.40.

Aytu BioPharma (NASDAQ:AYTU) last posted its quarterly earnings results on Thursday, September 26th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.37). Aytu BioPharma had a negative return on equity of 21.89% and a negative net margin of 8.28%. The business had revenue of $17.98 million during the quarter.

Institutional Investors Weigh In On Aytu BioPharma

Several institutional investors have recently bought and sold shares of AYTU. Dimensional Fund Advisors LP increased its stake in Aytu BioPharma by 54.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 23,551 shares of the company’s stock worth $69,000 after purchasing an additional 8,311 shares during the period. Armistice Capital LLC purchased a new position in shares of Aytu BioPharma in the second quarter worth $736,000. Finally, Stonepine Capital Management LLC increased its stake in shares of Aytu BioPharma by 6.0% in the third quarter. Stonepine Capital Management LLC now owns 500,958 shares of the company’s stock worth $1,177,000 after buying an additional 28,489 shares during the period. 33.49% of the stock is currently owned by hedge funds and other institutional investors.

About Aytu BioPharma

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.